World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
40101
World Ranking
18239
National Ranking
9098

Overview

Margaret von Mehren is affiliated with the Fox Chase Cancer Center in the United States. Their research primarily focuses on medical studies related to oncology, with particular attention to gastrointestinal tumors and sarcomas.

Their work covers several main fields of study, including:

  • Medicine

Within medicine, von Mehren has contributed extensively to subfields such as:

  • Pulmonary and Respiratory Medicine
  • Gastroenterology
  • Oncology
  • Surgery
  • Cardiology and Cardiovascular Medicine

The main topics addressed in von Mehren's research include:

  • Gastrointestinal Tumor Research and Treatment
  • Sarcoma Diagnosis and Treatment
  • Gastric Cancer Management and Outcomes
  • Cardiac Tumors and Thrombi
  • Gastrointestinal Disorders and Treatments
  • Vascular Tumors and Angiosarcomas
  • Neurofibromatosis and Schwannoma Cases

Von Mehren has published numerous papers, with some recent and notable examples being:

  • Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology (2022), Journal of the National Comprehensive Cancer Network
  • Gastrointestinal stromal tumours (2021), Nature Reviews Disease Primers
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial (2020), The Lancet Oncology
  • NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021 (2020), Journal of the National Comprehensive Cancer Network
  • Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial (2020), The Lancet Oncology

Frequent co-authors in von Mehren's publications include:

  • Suzanne George
  • Michael C. Heinrich
  • Robin L. Jones
  • Jonathan C. Trent
  • Sebastian Bauer

Publication venues where von Mehren's work has appeared commonly are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of the National Comprehensive Cancer Network
  • Cancer
  • Clinical Cancer Research

Best Publications

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

    Ronald P. DeMatteo;Karla V. Ballman;Cristina R. Antonescu;Robert G. Maki

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

    George D. Demetri;Margaret Von Mehren;Cristina R. Antonescu;Ronald P. DeMatteo

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

    George D. Demetri;Margaret von Mehren;Robin L. Jones;Martee L. Hensley

  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

    Michael C. Heinrich;Kouros Owzar;Christopher L. Corless;Donna Hollis

  • Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

    Margaret von Mehren;R. Lor Randall;Robert S. Benjamin;Sarah Boles

  • Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

    George D. Demetri;Sant P. Chawla;Margaret von Mehren;Paul Ritch

  • Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

    Burton L. Eisenberg;Jonathan Harris;Charles D. Blanke;George D. Demetri

  • Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

    George D. Demetri;Yanfeng Wang;Elisabeth Wehrle;Amy Racine

  • Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

    Anthony W. Tolcher;Monica Mita;Neal J. Meropol;Margaret von Mehren

  • Monoclonal antibody therapy for cancer.

    Margaret von Mehren;Gregory P. Adams;Louis M. Weiner

  • Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

    Sosipatros A. Boikos;Alberto S. Pappo;J. Keith Killian;Michael P. LaQuaglia

  • Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial

    Christopher L. Corless;Karla V. Ballman;Cristina R. Antonescu;Violetta Kolesnikova

Frequent Co-Authors

George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Michael Heinrich
Michael Heinrich Oregon Health & Science University
Suzanne George
Suzanne George Harvard University
Robert G. Maki
Robert G. Maki University of Pennsylvania
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Shreyaskumar Patel
Shreyaskumar Patel The University of Texas MD Anderson Cancer Center
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Heikki Joensuu
Heikki Joensuu University of Helsinki
Christopher L. Corless
Christopher L. Corless Oregon Health & Science University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees and career pathways can broaden your opportunities in medicine and healthcare. For nurses seeking leadership or advanced clinical roles, pursuing affordable dnp programs might be an excellent option. These programs offer flexibility and can lead to top-tier positions in patient care or academics, often at a more reasonable cost.

If you want to start your nursing career quickly, lpn online programs allow students to enter the workforce faster while still learning essential clinical skills. Many find this a smart stepping stone to more advanced nursing roles later on.

Those interested in mental health can consider the shortest online pmhnp programs. These help registered nurses specialize in psychiatric and mental health, addressing a critical need in healthcare today.

Finally, for aspiring administrators, enrolling in a health care administration online degree prepares you for leadership in clinics, hospitals, or healthcare organizations. Online options are often more affordable and flexible, making them suitable for working professionals.

Best Scientists Citing Margaret von Mehren

Trending Scientists

Recently Published Articles